Synergistic Ferroptosis–Immunotherapy Nanoplatforms: Multidimensional Engineering for Tumor Microenvironment Remodeling and Therapeutic Optimization
Open Access
- 2 September 2025
- journal article
- review article
- Published by Springer Nature in Nano-Micro Letters
- Vol. 18 (1) , 1-68
Abstract
Emerging ferroptosis–immunotherapy strategies, integrating functionalized nanoplatforms with ferroptosis-inducing agents and immunomodulatory therapeutics, demonstrate significant potential in managing primary, recurrent, and metastatic malignancies. Mechanistically, ferroptosis induction not only directly eliminates tumor cells but also promotes immunogenic cell death (ICD), eliciting damage-associated molecular patterns (DAMPs) release to activate partial antitumor immunity. However, standalone ferroptosis therapy fails to initiate robust systemic antitumor immune responses due to inherent limitations: low tumor immunogenicity, immunosuppressive microenvironment constraints, and tumor microenvironment (TME)-associated physiological barriers (e.g., hypoxia, dense extracellular matrix). To address these challenges, synergistic approaches have been developed to enhance immune cell infiltration and reestablish immunosurveillance, encompassing (1) direct amplification of antitumor immunity, (2) disruption of immunosuppressive tumor niches, and (3) biophysical hallmark remodeling in TME. Rational nanocarrier design has emerged as a critical enabler for overcoming biological delivery barriers and optimizing therapeutic efficacy. Unlike prior studies solely addressing ferroptosis or nanotechnology in tumor therapy, this work first systematically outlines the synergistic potential of nanoparticles in combined ferroptosis–immunotherapy strategies. It advances multidimensional nanoplatform design principles for material selection, structural configuration, physicochemical modulation, multifunctional integration, and artificial intelligence-enabled design, providing a scientific basis for efficacy optimization. Moreover, it examines translational challenges of ferroptosis–immunotherapy nanoplatforms across preclinical and clinical stages, proposing actionable solutions while envisioning future onco-immunotherapy directions. Collectively, it provides systematic insights into advanced nanomaterial design principles and therapeutic optimization strategies, offering a roadmap for accelerating clinical translation in onco-immunotherapy research.Keywords
This publication has 227 references indexed in Scilit:
- A Triple‐Responsive Polymeric Prodrug Nanoplatform with Extracellular ROS Consumption and Intracellular H2O2 Self‐Generation for Imaging‐Guided Tumor Chemo‐Ferroptosis‐ImmunotherapyAdvanced Healthcare Materials, 2024
- Metal‐Organic Framework‐Based Nanomedicines for Ferroptotic Cancer TherapyAdvanced Healthcare Materials, 2024
- Engineered Microbial Nanohybrids for Tumor‐Mediated NIR II Photothermal Enhanced Ferroptosis/Cuproptosis and ImmunotherapyAdvanced Healthcare Materials, 2023
- Photo‐Enhanced Synergistic Induction of Ferroptosis for Anti‐Cancer ImmunotherapyAdvanced Healthcare Materials, 2023
- Near‐Infrared Light‐Enhanced Generation of Hydroxyl Radical for Cancer ImmunotherapyAdvanced Healthcare Materials, 2023
- Ferroptosis and Pyroptosis Co‐Activated Nanomodulator for “Cold” Tumor Immunotherapy and Lung Metastasis InhibitionAdvanced Functional Materials, 2023
- Protease‐Activatable Nanozyme with Photoacoustic and Tumor‐Enhanced Magnetic Resonance Imaging for Photothermal Ferroptosis Cancer TherapyAdvanced Functional Materials, 2022
- Understanding Structure–Function Relationships of Nanoadjuvants for Enhanced Cancer Vaccine EfficacyAdvanced Functional Materials, 2022
- Anti‐PD‐L1 DNAzyme Loaded Photothermal Mn2+/Fe3+ Hybrid Metal‐Phenolic Networks for Cyclically Amplified Tumor Ferroptosis‐ImmunotherapyAdvanced Healthcare Materials, 2021
- pH‐Sensitive Molecular‐Switch‐Containing Polymer Nanoparticle for Breast Cancer Therapy with Ferritinophagy‐Cascade Ferroptosis and Tumor Immune ActivationAdvanced Healthcare Materials, 2021